Advertisement
MRNA vs RXRX
Which Stock Would AI Choose? Moderna (MRNA) vs. Recursion Pharmaceuticals (RXRX) Stock Comparison
Key Takeaways
- Moderna (MRNA) has delivered strong year-to-date gains in 2026 amid volatility, supported by its established mRNA platform and upcoming regulatory and earnings catalysts.
- Recursion Pharmaceuticals (RXRX) has experienced year-to-date declines, reflecting broader challenges in the biotech sector and its early-stage AI-driven drug discovery model.
- Both companies operate in biotechnology but differ significantly in scale, revenue maturity, and market positioning, with Moderna (MRNA) benefiting from commercial products and Recursion Pharmaceuticals (RXRX) focused on platform technology.
- Recent market activity shows Moderna (MRNA) with greater price momentum compared to Recursion Pharmaceuticals (RXRX), which has traded near multi-year lows.
- Sector exposure to healthcare innovation exposes both stocks to regulatory risks, clinical trial outcomes, and shifts in investor sentiment toward high-growth biotech names.
- Relative performance highlights trade-offs between Moderna (MRNA)’s established pipeline and Recursion Pharmaceuticals (RXRX)’s longer-term platform potential.
Introduction
This comparison examines Moderna (MRNA) and Recursion Pharmaceuticals (RXRX), two biotechnology companies leveraging advanced technologies in drug development. Moderna (MRNA) focuses on messenger RNA (mRNA) therapeutics and vaccines, while Recursion Pharmaceuticals (RXRX) applies artificial intelligence to accelerate small-molecule drug discovery. Investors and traders interested in healthcare innovation, growth-oriented biotech exposure, and relative performance between commercial-stage and platform-focused companies may find this analysis relevant for assessing market positioning and recent trends.
Moderna Overview and Recent Performance
Moderna (MRNA) develops mRNA-based medicines, including vaccines and therapeutics for infectious diseases, oncology, and rare conditions. The company’s platform gained prominence through its COVID-19 vaccine and continues to advance candidates in respiratory and cancer areas. In recent weeks, the stock has shown notable volatility following a period of strong gains earlier in 2026, with year-to-date returns significantly outperforming broader market benchmarks. Recent market activity reflects investor attention ahead of an FDA decision on its flu vaccine candidate and the upcoming second-quarter 2026 earnings report. Sentiment has been influenced by pipeline progress and board updates, though pullbacks have occurred amid broader market movements and pre-earnings positioning.
RXRX Overview and Recent Performance
Recursion Pharmaceuticals (RXRX) utilizes artificial intelligence and machine learning to map cellular biology and identify potential drug candidates at scale. The company’s platform aims to reduce traditional drug discovery timelines across multiple therapeutic areas. In recent weeks, the stock has traded lower amid ongoing sector pressures, with year-to-date performance reflecting declines consistent with many early-stage biotechnology names. Recent market activity shows the shares near the lower end of their recent range, influenced by clinical development updates and overall investor caution toward companies without approved products. Sentiment remains tied to platform validation milestones and financing needs typical of development-stage biotechs.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights select AI trading bots from a library of hundreds that analyze and trade thousands of different tickers. Only the highest-performing and most suitable bots for prevailing market conditions are featured in this curated section. Available bots cover a wide range of trading styles, strategies, timeframes, and performance statistics, with many demonstrating win rates between 60% and 80% or higher on historical backtests depending on the specific model. Users can review detailed metrics such as profit factors, maximum drawdowns, and ticker-specific applicability before exploring active signals. This resource provides traders with data-driven options for automated strategies across equities like those discussed here.
Head-to-Head Comparison
Moderna (MRNA) operates with a commercial-stage business model anchored by approved products and a diversified pipeline, contrasting with Recursion Pharmaceuticals (RXRX)’s platform-centric approach focused on AI-enabled discovery without marketed therapies. Growth drivers for Moderna (MRNA) include regulatory milestones and potential product launches, while Recursion Pharmaceuticals (RXRX) emphasizes long-term platform scalability and partnership opportunities. Recent momentum has favored Moderna (MRNA) with stronger year-to-date returns, whereas Recursion Pharmaceuticals (RXRX) has faced steeper relative declines. Risk factors for both include clinical and regulatory uncertainties, though Moderna (MRNA) carries additional commercialization risks and Recursion Pharmaceuticals (RXRX) faces higher development-stage execution risks. Sector exposure centers on biotechnology innovation, where market sentiment often rotates based on macroeconomic conditions and capital availability for growth companies.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative stability, and positioning around near-term catalysts, Tickeron’s AI would currently favor Moderna (MRNA) with moderate probability. The stock’s stronger year-to-date performance and upcoming events provide a clearer near-term framework compared to Recursion Pharmaceuticals (RXRX)’s more extended development horizon and recent price pressure. This assessment remains probabilistic and tied to evolving market data rather than definitive outcomes.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsTo compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Hold and RXRX is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRNA’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).
- MRNA’s FA Score: 1 green, 4 red.
- RXRX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRNA’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).
- MRNA’s TA Score: 4 bullish, 6 bearish.
- RXRX’s TA Score: 5 bullish, 5 bearish.
Price Growth
MRNA (@Biotechnology) experienced а -7.01% price change this week, while RXRX (@Biotechnology) price change was +4.61% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.94%. For the same industry, the average monthly price growth was +0.31%, and the average quarterly price growth was +2915.40%.
Reported Earning Dates
MRNA is expected to report earnings on Oct 29, 2026.
RXRX is expected to report earnings on Aug 11, 2026.
Industries' Descriptions
@Biotechnology (+6.94% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| MRNA | RXRX | MRNA / RXRX | |
| Capitalization | 23.6B | 1.74B | 1,358% |
| EBITDA | -2.8B | -478.66M | 586% |
| Gain YTD | 82.638 | -22.249 | -371% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 2.21B | 65.7M | 3,364% |
| Total Cash | 5.14B | 654M | 786% |
| Total Debt | 1.29B | 72.4M | 1,778% |
MRNA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 56 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 79 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 50 | |
P/E GROWTH RATING 1..100 | 3 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| MRNA | RXRX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 73% | 2 days ago 74% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 83% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 78% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 87% |
| Advances ODDS (%) | 5 days ago 79% | 2 days ago 83% |
| Declines ODDS (%) | 3 days ago 87% | 20 days ago 88% |
| BollingerBands ODDS (%) | 5 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 77% |
Advertisement